Published in Gene Therapy Weekly, September 28th, 1998
Most enzyme/prodrug systems are based on herpes simplex virus type 1 thymidine kinase and the antiviral drug ganciclovir or cytosine deaminase and the prodrug 5-fluorocytosine. These suicide gene therapy combinations work as antimetabolites, whose toxicity is dependent upon ongoing DNA replication. As such, growth-arrested cells are not significantly altered by these therapies and their application to some cancers is limited.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.